Skip to main content
Top
Published in: Inflammation 1/2018

01-02-2018 | ORIGINAL ARTICLE

Cepharanthine Inhibits IFN-γ-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells

Authors: Keiko Aota, Tomoko Yamanoi, Koichi Kani, Masayuki Azuma

Published in: Inflammation | Issue 1/2018

Login to get access

Abstract

Cepharanthine, a biscolaurine alkaloid isolated from the plant Stephania cephalantha Hayata, has been reported to have potent anti-inflammatory properties. Here, we investigated the effects of cepharanthine on the expression of CXCL10 (a CXC chemokine induced by interferon-gamma [IFN-γ] that has been observed in a wide variety of chronic inflammatory disorders and autoimmune conditions) in IFN-γ-treated human salivary gland cell lines. We observed that IFN-γ-induced CXCL10 production in NS-SV-DC cells (a human salivary gland ductal cell line), but not in NS-SV-AC cells (a human salivary gland acinar cell line). Cepharanthine inhibited the IFN-γ-induced CXCL10 production in NS-SV-DC cells. A Western blot analysis showed that cepharanthine prevented the phosphorylation of JAK2 and STAT1, but did not interfere with the NF-κB pathway. Moreover, cepharanthine inhibited the IFN-γ-mediated chemotaxis of Jurkat T cells. These results suggest that cepharanthine suppresses IFN-γ-induced CXCL10 production via the inhibition of the JAK2/STAT1 signaling pathway in human salivary gland ductal cells. Our findings also indicate that cepharanthine could inhibit the chemotaxis of Jurkat T cells by reducing CXCL10 production.
Literature
1.
go back to reference Alspaugh, M.A., and K. Whaley. 1981. In Sjögren’s syndrome, textbook of Rheumatology, ed. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, 971–999. Philadelphia: W.B. Saunders. Alspaugh, M.A., and K. Whaley. 1981. In Sjögren’s syndrome, textbook of Rheumatology, ed. W.N. Kelley, E.D. Harris, S. Ruddy, and C.B. Sledge, 971–999. Philadelphia: W.B. Saunders.
2.
go back to reference Daniels, T.E. 1984. Labial salivary gland biopsy in Sjögren's syndrome: Assessment as a diagnostic criterion in 362 suspected cases. Arthritis and Rheumatism 27: 147–156.CrossRefPubMed Daniels, T.E. 1984. Labial salivary gland biopsy in Sjögren's syndrome: Assessment as a diagnostic criterion in 362 suspected cases. Arthritis and Rheumatism 27: 147–156.CrossRefPubMed
3.
go back to reference Hamano, H., I. Saito, N. Haneji, Y. Mitsuhashi, and Hayashi Y. MiyasakaN. 1993. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. European Journal of Immunology 23: 2387–2391.CrossRefPubMed Hamano, H., I. Saito, N. Haneji, Y. Mitsuhashi, and Hayashi Y. MiyasakaN. 1993. Expressions of cytokine genes during development of autoimmune sialadenitis in MRL/lpr mice. European Journal of Immunology 23: 2387–2391.CrossRefPubMed
4.
go back to reference Fox, R.I., H.I. Kang, D. Ando, J. Abrams, and E. Pisa. 1994. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. Journal of Immunology 152: 5532–5529. Fox, R.I., H.I. Kang, D. Ando, J. Abrams, and E. Pisa. 1994. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. Journal of Immunology 152: 5532–5529.
6.
go back to reference Hall, J.C., A.N. Baer, A.A. Shah, L.A. Criswell, C.H. Shiboski, A. Rosen, and L. Casciola-Rosen. 2015. Molecular subsetting of interferon pathways in Sjögren's syndrome. Arthritis & Rhematology 67: 2437–2446.CrossRef Hall, J.C., A.N. Baer, A.A. Shah, L.A. Criswell, C.H. Shiboski, A. Rosen, and L. Casciola-Rosen. 2015. Molecular subsetting of interferon pathways in Sjögren's syndrome. Arthritis & Rhematology 67: 2437–2446.CrossRef
7.
go back to reference Nocturne, G., and X. Mariette. 2013. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nature Reviews. Rheumatology 9: 544–556.CrossRefPubMed Nocturne, G., and X. Mariette. 2013. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nature Reviews. Rheumatology 9: 544–556.CrossRefPubMed
8.
go back to reference Luster, A.D., J.C. Unkeless, and J.V. Ravetch. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672–676.CrossRefPubMed Luster, A.D., J.C. Unkeless, and J.V. Ravetch. 1985. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315: 672–676.CrossRefPubMed
9.
go back to reference García-López, M.A., F. Sánchez-Madrid, J.M. Rodríguez-Frade, M. Mellado, A. Acevedo, M.I. García, J.P. Albar, C. Martínez, and M. Marazuela. 2001. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Laboratory Investigation 81: 409–418.CrossRefPubMed García-López, M.A., F. Sánchez-Madrid, J.M. Rodríguez-Frade, M. Mellado, A. Acevedo, M.I. García, J.P. Albar, C. Martínez, and M. Marazuela. 2001. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells. Laboratory Investigation 81: 409–418.CrossRefPubMed
10.
go back to reference Groom, J.R., and A.D. Luster. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology 89: 207–215.CrossRefPubMed Groom, J.R., and A.D. Luster. 2011. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunology and Cell Biology 89: 207–215.CrossRefPubMed
11.
go back to reference Hartl, D., S. Krauss-Etschmann, B. Koller, P.L. Hordijk, T.W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, O. Eickelberg, M. Griese, and D. Roos. 2008. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. Journal of Immunology 181: 8053–8067.CrossRef Hartl, D., S. Krauss-Etschmann, B. Koller, P.L. Hordijk, T.W. Kuijpers, F. Hoffmann, A. Hector, E. Eber, V. Marcos, I. Bittmann, O. Eickelberg, M. Griese, and D. Roos. 2008. Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases. Journal of Immunology 181: 8053–8067.CrossRef
12.
go back to reference Tomita, K., B.L. Freeman, S.F. Bronk, N.K. LeBrasseur, T.A. White, P. Hirsova, and S.H. Ibrahim. 2016. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Scientific Reports 6: 28786.CrossRefPubMedPubMedCentral Tomita, K., B.L. Freeman, S.F. Bronk, N.K. LeBrasseur, T.A. White, P. Hirsova, and S.H. Ibrahim. 2016. CXCL10-mediates macrophage, but not other innate immune cells-associated inflammation in murine nonalcoholic steatohepatitis. Scientific Reports 6: 28786.CrossRefPubMedPubMedCentral
13.
go back to reference Ogawa, N., L. Ping, L. Zhenjun, Y. Takada, and S. Sugai. 2002. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ-inducible 10-kD protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis and Rheumatism 46: 2730–2741.CrossRefPubMed Ogawa, N., L. Ping, L. Zhenjun, Y. Takada, and S. Sugai. 2002. Involvement of the interferon-γ-induced T cell-attracting chemokines, interferon-γ-inducible 10-kD protein (CXCL10) and monokine induced by interferon-γ (CXCL9), in the salivary gland lesions of patients with Sjögren's syndrome. Arthritis and Rheumatism 46: 2730–2741.CrossRefPubMed
14.
go back to reference Ogawa, N., T. Kawanami, K. Shimoyama, L. Ping, and S. Sugai. 2004. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren’s syndrome. Clinical Immunology 112: 235–238.CrossRefPubMed Ogawa, N., T. Kawanami, K. Shimoyama, L. Ping, and S. Sugai. 2004. Expression of interferon-inducible T cell alpha chemoattractant (CXCL11) in the salivary glands of patients with Sjögren’s syndrome. Clinical Immunology 112: 235–238.CrossRefPubMed
15.
go back to reference Hasegawa, H., A. Inoue, M. Kohno, M. Muraoka, T. Miyazaki, M. Terada, T. Nakayama, O. Yoshie, M. Nose, and M. Yasukawa. 2006. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis and Rheumatism 54: 1174–1183.CrossRefPubMed Hasegawa, H., A. Inoue, M. Kohno, M. Muraoka, T. Miyazaki, M. Terada, T. Nakayama, O. Yoshie, M. Nose, and M. Yasukawa. 2006. Antagonist of interferon-inducible protein 10/CXCL10 ameliorates the progression of autoimmune sialadenitis in MRL/lpr mice. Arthritis and Rheumatism 54: 1174–1183.CrossRefPubMed
16.
go back to reference Gutterman, J.U., S. Fine, J. Quesada, S.J. Horning, J.F. Levine, R. Alexanian, L. Bernhardt, M. Kramer, H. Spiegel, W. Colburn, P. Trown, T. Merigan, and Z. Dziewanowski. 1982. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Annals of Internal Medicine 96: 549–556.CrossRefPubMed Gutterman, J.U., S. Fine, J. Quesada, S.J. Horning, J.F. Levine, R. Alexanian, L. Bernhardt, M. Kramer, H. Spiegel, W. Colburn, P. Trown, T. Merigan, and Z. Dziewanowski. 1982. Recombinant leukocyte A interferon: Pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients. Annals of Internal Medicine 96: 549–556.CrossRefPubMed
17.
go back to reference Ono, M. 1987. Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clinical Immunology 19: 1061–1064. Ono, M. 1987. Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clinical Immunology 19: 1061–1064.
18.
go back to reference Morioka, S., M. Ono, N. Tanaka, and K. Orita. 1985. Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Gan to Kagaku Ryoho 12: 1470–1475.PubMed Morioka, S., M. Ono, N. Tanaka, and K. Orita. 1985. Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Gan to Kagaku Ryoho 12: 1470–1475.PubMed
19.
go back to reference Azuma, M., K. Aota, T. Tamatani, K. Motegi, T. Yamashita, Y. Ashida, Y. Hayashi, and M. Sato. 2002. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: A possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis and Rheumatism 46: 1585–1594.CrossRefPubMed Azuma, M., K. Aota, T. Tamatani, K. Motegi, T. Yamashita, Y. Ashida, Y. Hayashi, and M. Sato. 2002. Suppression of tumor necrosis factor α-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor κB: A possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjögren's syndrome patients. Arthritis and Rheumatism 46: 1585–1594.CrossRefPubMed
20.
go back to reference Azuma, M., Y. Ashida, T. Tamatani, K. Motegi, N. Takamaru, N. Ishimaru, Y. Hayashi, and M. Sato. 2006. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren’s syndrome. The Journal of Rheumatology 33: 912–920.PubMed Azuma, M., Y. Ashida, T. Tamatani, K. Motegi, N. Takamaru, N. Ishimaru, Y. Hayashi, and M. Sato. 2006. Cepharanthin, a biscoclaurine alkaloid, prevents destruction of acinar tissues in murine Sjögren’s syndrome. The Journal of Rheumatology 33: 912–920.PubMed
21.
go back to reference Yamanoi, T., K. Aota, Y. Momota, and M. Azuma. 2017. Treatment with the biscoclaurine alkaloid cepharanthin for improved salivary secretion in primary Sjögren's syndrome patients. Journal of Oral Health Biosciences 29: 39–48. Yamanoi, T., K. Aota, Y. Momota, and M. Azuma. 2017. Treatment with the biscoclaurine alkaloid cepharanthin for improved salivary secretion in primary Sjögren's syndrome patients. Journal of Oral Health Biosciences 29: 39–48.
22.
go back to reference Azuma, M., T. Tamatani, Y. Kasai, and M. Sato. 1993. Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection of SV40 ori-mutant DNA. Laboratory Investigation 69: 24–42.PubMed Azuma, M., T. Tamatani, Y. Kasai, and M. Sato. 1993. Immortalization of normal human salivary gland cells with duct-, myoepithelial-, acinar-, or squamous phenotype by transfection of SV40 ori-mutant DNA. Laboratory Investigation 69: 24–42.PubMed
23.
go back to reference Hogan, J.C., and J.M. Stephens. 2001. The identification and characterization of a STAT 1 binding site in the PPARγ2 promoter. Biochemical and Biophysical Research Communications 287: 484–492.CrossRefPubMed Hogan, J.C., and J.M. Stephens. 2001. The identification and characterization of a STAT 1 binding site in the PPARγ2 promoter. Biochemical and Biophysical Research Communications 287: 484–492.CrossRefPubMed
24.
go back to reference Majumder, S., L.Z. Zhou, P. Chaturvedi, G. Babcock, S. Aras, and R.M. Ransohoff. 1998. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161: 4736–4744. Majumder, S., L.Z. Zhou, P. Chaturvedi, G. Babcock, S. Aras, and R.M. Ransohoff. 1998. p48/STAT-1alpha-containing complexes play a predominant role in induction of IFN-gamma-inducible protein, 10 kDa (IP-10) by IFN-gamma alone or in synergy with TNF-alpha. Journal of Immunology 161: 4736–4744.
25.
go back to reference Azuma, M., K. Motegi, K. Aota, Y. Hayashi, and M. Sato. 1997. Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Laboratory Investigation 77: 269–280.PubMed Azuma, M., K. Motegi, K. Aota, Y. Hayashi, and M. Sato. 1997. Role of cytokines in the destruction of acinar structure in Sjögren’s syndrome salivary glands. Laboratory Investigation 77: 269–280.PubMed
26.
go back to reference Hall, J.C., L. Casciola-Rosen, A.E. Berger, E.K. Kapsogeorgou, C. Cheadle, A.G. Tzioufas, A.N. Baer, and A. Rosen. 2012. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America 109: 17609–17614.CrossRefPubMedPubMedCentral Hall, J.C., L. Casciola-Rosen, A.E. Berger, E.K. Kapsogeorgou, C. Cheadle, A.G. Tzioufas, A.N. Baer, and A. Rosen. 2012. Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proceedings of the National Academy of Sciences of the United States of America 109: 17609–17614.CrossRefPubMedPubMedCentral
27.
go back to reference Lacotte, S., S. Brun, S. Muller, and H. Dumortier. 2009. CXCR3, inflammation, and autoimmune diseases. Annals of the New York Academy of Sciences 1173: 310–317.CrossRefPubMed Lacotte, S., S. Brun, S. Muller, and H. Dumortier. 2009. CXCR3, inflammation, and autoimmune diseases. Annals of the New York Academy of Sciences 1173: 310–317.CrossRefPubMed
28.
go back to reference Gangur, V., F.E. Simons, and K.T. Hayglass. 1998. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. The FASEB Journal 12: 705–713.PubMed Gangur, V., F.E. Simons, and K.T. Hayglass. 1998. Human IP-10 selectively promotes dominance of polyclonally activated and environmental antigen-driven IFN-gamma over IL-4 responses. The FASEB Journal 12: 705–713.PubMed
29.
go back to reference Qi, X.F., D.H. Kim, Y.S. Yoon, D. Jin, X.Z. Huang, J.H. Li, Y.K. Deung, and K.J. Lee. 2009. Essential involvement of cross-talk between IFN-γ and TNF-α in CXCL10 production in human THP-1 monocytes. Journal of Cellular Physiology 220: 690–697.CrossRefPubMed Qi, X.F., D.H. Kim, Y.S. Yoon, D. Jin, X.Z. Huang, J.H. Li, Y.K. Deung, and K.J. Lee. 2009. Essential involvement of cross-talk between IFN-γ and TNF-α in CXCL10 production in human THP-1 monocytes. Journal of Cellular Physiology 220: 690–697.CrossRefPubMed
30.
go back to reference Kelner, G.S., J. Kennedy, K.B. Bacon, S. Kleyensteuber, D.A. Largaespada, N.A. Jenkins, N.G. Copeland, J.F. Bazan, K.W. Moore, T.J. Schall, et al. 1994. Lymphotactin: A cytokine that represents a new class of chemokine. Science 266: 1395–1399.CrossRefPubMed Kelner, G.S., J. Kennedy, K.B. Bacon, S. Kleyensteuber, D.A. Largaespada, N.A. Jenkins, N.G. Copeland, J.F. Bazan, K.W. Moore, T.J. Schall, et al. 1994. Lymphotactin: A cytokine that represents a new class of chemokine. Science 266: 1395–1399.CrossRefPubMed
31.
go back to reference Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032–3043.PubMed Murdoch, C., and A. Finn. 2000. Chemokine receptors and their role in inflammation and infectious diseases. Blood 95: 3032–3043.PubMed
Metadata
Title
Cepharanthine Inhibits IFN-γ-Induced CXCL10 by Suppressing the JAK2/STAT1 Signal Pathway in Human Salivary Gland Ductal Cells
Authors
Keiko Aota
Tomoko Yamanoi
Koichi Kani
Masayuki Azuma
Publication date
01-02-2018
Publisher
Springer US
Published in
Inflammation / Issue 1/2018
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-017-0662-x

Other articles of this Issue 1/2018

Inflammation 1/2018 Go to the issue